These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25895459)

  • 1. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
    Li R; Shi X; Ling F; Wang C; Liu J; Wang W; Li M
    Tumour Biol; 2015 Sep; 36(9):7277-83. PubMed ID: 25895459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.
    Mudduluru G; Ceppi P; Kumarswamy R; Scagliotti GV; Papotti M; Allgayer H
    Oncogene; 2011 Jun; 30(25):2888-99. PubMed ID: 21317930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-34a inhibits cell invasion and epithelial-mesenchymal transition via targeting AXL/PI3K/AKT/Snail signaling in nasopharyngeal carcinoma.
    Jiang C; Cheng Z; Jiang T; Xu Y; Wang B
    Genes Genomics; 2020 Aug; 42(8):971-978. PubMed ID: 32648233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
    Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p.
    Li YY; Tao YW; Gao S; Li P; Zheng JM; Zhang SE; Liang J; Zhang Y
    EBioMedicine; 2018 Oct; 36():209-220. PubMed ID: 30243489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets
    Hajalirezay Yazdi S; Paryan M; Mohammadi-Yeganeh S
    Cell Mol Biol Lett; 2018; 23():51. PubMed ID: 30386383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
    Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
    World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of
    Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
    Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels.
    Fritz HK; Gustafsson A; Ljungberg B; Ceder Y; Axelson H; Dahlbäck B
    PLoS One; 2015; 10(8):e0135991. PubMed ID: 26287733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells.
    Lim D; Cho JG; Yun E; Lee A; Ryu HY; Lee YJ; Yoon S; Chang W; Lee MS; Kwon BS; Kim J
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
    Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
    Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
    El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
    J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent downregulation of miR-34 family in human ovarian cancers.
    Corney DC; Hwang CI; Matoso A; Vogt M; Flesken-Nikitin A; Godwin AK; Kamat AA; Sood AK; Ellenson LH; Hermeking H; Nikitin AY
    Clin Cancer Res; 2010 Feb; 16(4):1119-28. PubMed ID: 20145172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells.
    Cho CY; Huang JS; Shiah SG; Chung SY; Lay JD; Yang YY; Lai GM; Cheng AL; Chen LT; Chuang SE
    RNA; 2016 Feb; 22(2):303-15. PubMed ID: 26667302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.
    Zhu H; Jin YM; Lyu XM; Fan LM; Wu F
    Cell Cycle; 2019 Oct; 18(19):2454-2464. PubMed ID: 31411527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL.
    Nam RK; Benatar T; Wallis CJD; Kobylecky E; Amemiya Y; Sherman C; Seth A
    Prostate; 2019 Sep; 79(12):1422-1438. PubMed ID: 31269290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer.
    Ibrahim FF; Jamal R; Syafruddin SE; Ab Mutalib NS; Saidin S; MdZin RR; Hossain Mollah MM; Mokhtar NM
    J Ovarian Res; 2015 Aug; 8():56. PubMed ID: 26260454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
    Kim NY; Lee HY; Lee C
    Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma.
    Hong Q; Li O; Zheng W; Xiao WZ; Zhang L; Wu D; Cai GY; He JC; Chen XM
    Cell Death Dis; 2017 May; 8(5):e2772. PubMed ID: 28492542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
    Rankin EB; Fuh KC; Taylor TE; Krieg AJ; Musser M; Yuan J; Wei K; Kuo CJ; Longacre TA; Giaccia AJ
    Cancer Res; 2010 Oct; 70(19):7570-9. PubMed ID: 20858715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.